T&R Biofab Co. Ltd (246710) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of T&R Biofab Co. Ltd KRW 309, price KRW 2,320, upside -86.7%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch T&R Biofab Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range 1,194 KRW – 29,229 KRW · fair‑value band 230.54 KRW – 461.07 KRW · the 2,320 KRW price screens above the 308.92 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow T&R Biofab Co. in your weekly email
Every Wednesday you see whether T&R Biofab Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.
Stock analysis
T&R Biofab Co. Ltd (246710) currently trades at 2,320 KRW, while our model-based Fair Value estimate is 308.92 KRW, 86.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 230.54 KRW (bear) to 461.07 KRW (bull), the price of 2,320 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
T&R Biofab Co. Ltd reported revenue of 27.0B KRW in FY2025 versus 3.2B KRW in FY2021, a compound +69.9%/yr. Reported net income was −34.9B KRW in FY2025.
Key figures
Market cap 98.9B KRW (≈ $73.7M) · P/S ratio 3.33 · Net margin −130% · Return on equity −146% · Return on assets (EBIT) −11.0% · Operating margin −10.7% · Revenue (TTM) 29.7B KRW · Revenue growth (YoY) +46.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 94% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −87%, 246710 screens richer than that median.
Fair Value models
Bear 230.54 KRWFair Value 308.92 KRWBull 461.07 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+453.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.7%
Start year 2020 (pandemic). Over 10 years: +80.6% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−81.0% (2020) → −31.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score21 · Bottom 25%
Fair Value upside−86.7% · Bottom 25%
Profitability
Return on assets−4.0% · Below median
Net margin (TTM)−105.0% · Bottom 25%
Operating margin (TTM)−10.7% · Bottom 25%
Growth and dividend
Revenue growth46.5% · Top 25%
Balance sheet
Debt / equity1.00× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)100· sector 29
PAST (return on equity)0· sector 16
HEALTH (low debt)50· sector 98
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is T&R Biofab Co. Ltd (246710) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 308.92 KRW versus a price of 2,320 KRW, about −87% upside (overvalued).
What is the fair value of 246710?
Our model-based fair value for T&R Biofab Co. Ltd is 308.92 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 2,320 KRW.
What is the quality score of 246710?
T&R Biofab Co. Ltd has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for T&R Biofab Co. Ltd (246710)?
Our model-based price target is the fair value of 308.92 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 230.54 KRW, optimistic scenario 461.07 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the T&R Biofab Co. Ltd stock forecast for 2026?
Our models put fair value at 308.92 KRW, about −87% upside versus a price of 2,320 KRW (overvalued). Cautious scenario 230.54 KRW, optimistic scenario 461.07 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of T&R Biofab Co. Ltd (246710)?
T&R Biofab Co. Ltd reported trailing-twelve-month revenue of about 29.7B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of T&R Biofab Co. Ltd (246710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For T&R Biofab Co. Ltd it is 308.92 KRW per share (as of Oct 2, 2026), against a price of 2,320 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is T&R Biofab Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 246710 trades above its calculated fair value: price 2,320 KRW, fair value 308.92 KRW, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 246710?
No. The price is what the market pays today (2,320 KRW); the fair value is what the company's own numbers justify (308.92 KRW). For T&R Biofab Co. Ltd the two are 2,011 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is T&R Biofab Co. Ltd worth?
The market values T&R Biofab Co. Ltd at about 98.9B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 2,320 KRW; our models calculate a fair value of 308.92 KRW per share.
What do the bullish and bearish scenarios say about 246710?
Our models span a range for T&R Biofab Co. Ltd: cautious scenario 230.54 KRW, base 308.92 KRW, optimistic 461.07 KRW per share (as of Oct 2, 2026, price 2,320 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of T&R Biofab Co. Ltd (246710)?
Balance-sheet figures for T&R Biofab Co. Ltd (as of Oct 2, 2026): return on equity −146.1%, debt of 1.00 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is 246710 from its 52-week high?
T&R Biofab Co. Ltd trades at 2,320 KRW, about 49% below its 52-week high of 4,535 KRW and 94% above the low of 1,194 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 308.92 KRW is for.
Which stocks are comparable to T&R Biofab Co. Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is T&R Biofab Co. Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price 2,320 KRW, calculated fair value 308.92 KRW (−87%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 246710 calculated?
We run T&R Biofab Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 308.92 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. T&R Biofab Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of T&R Biofab Co. Ltd (246710)?
The closing price on Oct 2, 2026 was 2,320 KRW. Our model-based fair value is 308.92 KRW, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with T&R Biofab Co. Ltd right now?
The price sits above even our optimistic bull case (461.07 KRW). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (230.54 KRW to 461.07 KRW) leaves room in how you read the outcome.
Key figures of T&R Biofab Co. Ltd
How large is the market capitalisation of T&R Biofab Co. Ltd (246710)?
The market capitalisation of T&R Biofab Co. Ltd is 98.9B KRW (≈ $73.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of T&R Biofab Co. Ltd (246710)?
The price-to-sales ratio of T&R Biofab Co. Ltd is 3.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of T&R Biofab Co. Ltd (246710)?
The net margin of T&R Biofab Co. Ltd is −130% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of T&R Biofab Co. Ltd (246710)?
The return on equity (ROE) of T&R Biofab Co. Ltd is −146% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of T&R Biofab Co. Ltd (246710)?
On an EBIT basis the return on assets of T&R Biofab Co. Ltd is −11.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of T&R Biofab Co. Ltd (246710)?
The operating margin of T&R Biofab Co. Ltd is −10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at T&R Biofab Co. Ltd (246710)?
Revenue at T&R Biofab Co. Ltd is growing +46.5% versus a year earlier (3y avg +67.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does T&R Biofab Co. Ltd (246710) generate?
The free cash flow of T&R Biofab Co. Ltd is −9.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does T&R Biofab Co. Ltd (246710) carry?
The net debt of T&R Biofab Co. Ltd is 20.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch T&R Biofab Co. Ltd in the live analysis
One click puts T&R Biofab Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
